3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
4
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Carcinoma, Renal Cell
2
von Hippel-Lindau Disease
1
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
palbociclib
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled